Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Next Previous
Trial Profile

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Taladegib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors Endeavor Pharmaceuticals

Most Recent Events

  • 10 Sep 2025 According to an Endeavor BioMedicines Media Release, company announced that data from this trial have been selected for an ALERT (Abstracts Leading to Evolution in Respiratory Medicine Trials) session at the ERS Congress 2025 - a special forum highlighting high-impact, practice-changing clinical trials in respiratory medicine. The ERS Congress 2025 will take place from September 27 to October 1 in Amsterdam.
  • 20 May 2025 According to an Endeavor BioMedicines Media Release, new clinical findings from a post-hoc analysis from the completed Phase 2a clinical trial were presented in a poster presentation at the American Thoracic Society (ATS) 2025 International Conference.
  • 22 May 2024 Results presented at the 120th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top